Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/1474835/000165495418001992/a20-f.htm
SEC Filings
IPCI Annual Reports
IPCI Corporate News
6-K Foreign Issuer Report March 2019
6-K Foreign Issuer Report March 2019
6-K Foreign Issuer Report March 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report February 2019
6-K Foreign Issuer Report January 2019
6-K Foreign Issuer Report January 2019
6-K Foreign Issuer Report December 2018
6-K Foreign Issuer Report
March 2019
6-K Foreign Issuer Report
March 2019
6-K Foreign Issuer Report
March 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
February 2019
6-K Foreign Issuer Report
January 2019
6-K Foreign Issuer Report
January 2019
6-K Foreign Issuer Report
December 2018
Last10K.com | 20-F Annual Report Thu Mar 01 2018
View differences made from one year to another to evaluate Intellipharmaceutics International Inc.'s financial trajectory
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Intellipharmaceutics International Inc..
Assess how Intellipharmaceutics International Inc.'s management team is paid from their Annual Proxy
Intellipharmaceutics International Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 20-F Annual Report
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Shareholders' Equity (deficiency)
Document And Entity Information
Note 1 - Nature Of Operations
Note 1 - Nature Of Operations (details Narrative)
Note 10 - Capital Stock
Note 10 - Capital Stock (details Narrative)
Note 11 - Options
Note 11 - Options (details 1)
Note 11 - Options (details 2)
Note 11 - Options (details 3)
Note 11 - Options (details Narrative)
Note 11 - Options (details)
Note 11 - Options (tables)
Note 12 - Deferred Share Units
Note 12 - Deferred Share Units (details Narrative)
Note 12 - Deferred Share Units (details)
Note 12 - Deferred Share Units (tables)
Note 13 - Restricted Share Units
Note 13 - Restricted Share Units (details Narrative)
Note 14 - Warrants
Note 14 - Warrants (details 1)
Note 14 - Warrants (details Narrative)
Note 14 - Warrants (details)
Note 14 - Warrants (tables)
Note 15 - Income Taxes
Note 15 - Income Taxes (details 1)
Note 15 - Income Taxes (details 2)
Note 15 - Income Taxes (details Narrative)
Note 15 - Income Taxes (details)
Note 15 - Income Taxes (tables)
Note 16 - Contingencies
Note 17 - Financial Instruments
Note 17 - Financial Instruments (details 1)
Note 17 - Financial Instruments (details 2)
Note 17 - Financial Instruments (details Narrative)
Note 17 - Financial Instruments (details)
Note 17 - Financial Instruments (tables)
Note 18 - Segmented Information
Note 18 - Segmented Information (details)
Note 18 - Segmented Information (tables)
Note 2 - Basis Of Presentation
Note 3 - Significant Accounting Policies
Note 3 - Significant Accounting Policies (details Narrative)
Note 3 - Significant Accounting Policies (details)
Note 3 - Significant Accounting Policies (policies)
Note 3 - Significant Accounting Policies (tables)
Note 4 - Accounts Receivable
Note 4 - Accounts Receivable (details Narrative)
Note 5 - Property And Equipment
Note 5 - Property And Equipment (details Narrative)
Note 5 - Property And Equipment (details)
Note 5 - Property And Equipment (tables)
Note 6 - Accrued Liabilities
Note 6 - Accrued Liabilities (details)
Note 6 - Accrued Liabilities (tables)
Note 7 - Due To Related Parties
Note 7 - Due To Related Parties (details Narrative)
Note 7 - Due To Related Parties (details)
Note 7 - Due To Related Parties (tables)
Note 8 - Employee Costs Payable
Note 8 - Employee Costs Payable (details Narrative)
Note 9 - Lease Obligations
Note 9 - Lease Obligations (details Narrative)
Note 9 - Lease Obligations (details)
Note 9 - Lease Obligations (tables)
Material Contracts, Statements, Certifications & more
Intellipharmaceutics International Inc. provided additional information to their SEC Filing as exhibits
Exhibit 4.79: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 4.80: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 8.1: Opinion Regarding Tax Matters
Exhibit 12.1: Statement Regarding Calculation Of Ratios
Exhibit 12.2: Statement Regarding Calculation Of Ratios
Exhibit 13.1: Report To Security Holders
Exhibit 13.2: Report To Security Holders
Exhibit 15.1: Letter Regards Unaudited Interim Financial Information
Exhibit 15.2: Letter Regards Unaudited Interim Financial Information
Ticker: IPCI
CIK: 1474835
Form Type: 20-F Annual Report
Accession Number: 0001654954-18-001992
Submitted to the SEC: Thu Mar 01 2018 6:43:41 AM EST
Accepted by the SEC: Thu Mar 01 2018
Period: Wednesday, February 28, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/ipci/0001654954-18-001992.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...